Ondine Biomedical Announces Selection of Two Abstracts for Presentation at the 2026 World Congress on Infectious Diseases

Ondine Biomedical Inc. (LON: OBI), a leader in photodisinfection-based therapies, is pleased to announce that two of its abstracts have been accepted for poster presentation at the upcoming World Congress on Infectious Diseases, taking place 25-27 June 2026 in Barcelona, Spain.

The abstracts highlight the long-term clinical and economic impact of Ondine’s light-activated antimicrobial technology in surgical settings. Notably, the presentations will feature 8-year longitudinal data demonstrating the technology's improved outcomes compared to traditional antibiotic treatments.

One of the featured presentations, Breaking the Mupirocin Paradox: Light Activated Nasal Decolonization Achieves 66% SSI Reduction and Sustained Cost Savings Without Resistance Signals in Spine Surgery over 8 Years, underscores the efficacy of nasal photodisinfection in highly complex surgical environments over many years with no evidence of generating resistance. The study details how the non-antibiotic approach successfully mitigates issues associated with antibiotic resistance while maintaining a significant reduction in Surgical Site Infections (“SSIs”).

The second abstract, The Double Whammy of Cardiac SSI Under-Reporting: Correcting Incidence and Inflation to Unlock Capacity and Eradicate AMR Debt, addresses limitations in infection control caused by using unadjusted cost data and short-term SSI rates. This practice understates costs and impact, potentially limiting necessary changes for improved outcomes.

Carolyn Cross, CEO of Ondine Biomedical, emphasised the clinical significance of these findings:

"Nasal photodisinfection has demonstrated sustained reductions in SSI rates over many years without any observed loss of efficacy. This represents a key advantage of our light-activated, non-antibiotic antimicrobial therapy over topical antibiotics. By avoiding the development of antimicrobial resistance associated with traditional treatments, we are providing a durable solution for patient safety in highly complex surgical environments."

The World Congress on Infectious Diseases is a global platform for clinicians and researchers to share breakthroughs in combating antimicrobial resistance and hospital-acquired infections. Ondine’s research will be presented in the Poster Presentation (Virtual) category, allowing for broad international engagement with the findings.